This skill suggests using rapid-acting insulin analogs instead of regular human insulin for prandial bolus dosing in basal-bolus therapy for patients at high risk of hypoglycemia. It is triggered by clinician questions such as "Should I use rapid-acting analogs or regular insulin for prandial therapy in this high-risk patient?" or "Is rapid-acting analog insulin preferred for this patient?"
Installs into .claude/skills of the current project.
Are you the author of Es Rapid Acting Analog Vs Regular Insulin Bolus?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-es-rapid-acting-analog-vs-regular-insulin-bolus)
---
name: es-rapid-acting-analog-vs-regular-insulin-bolus
description: This skill suggests using rapid-acting insulin analogs instead of regular human insulin for prandial bolus dosing in basal-bolus therapy for patients at high risk of hypoglycemia. It is triggered by clinician questions such as "Should I use rapid-acting analogs or regular insulin for prandial therapy in this high-risk patient?" or "Is rapid-acting analog insulin preferred for this patient?"
---
# Rapid-Acting Analog vs Regular Insulin for Basal-Bolus Therapy
## STEP 1 — Gather Information
Confirm the patient is on basal-bolus insulin therapy and assess for high-risk hypoglycemia factors: history of severe hypoglycemia requiring assistance, impaired awareness of hypoglycemia (IAH), renal or hepatic dysfunction. Record age (adult/pediatric) and current insulin regimen.
## STEP 2 — Rule In / Rule Out
Determine if the patient meets high-risk criteria. If yes, proceed to Step 3; if not, regular insulin may be acceptable and move to Step 4.
## STEP 3 — Classify or Stratify
If high risk, classify for rapid-acting analog preference; if not high risk, note that either rapid-acting analog or regular insulin may be used based on other factors.
## STEP 4 — Decide
For high-risk patients, prescribe a rapid-acting insulin analog (e.g., aspart, lispro, glulisine) for mealtime bolus. For non-high-risk patients, choose insulin type considering cost, access, and patient preference.
## Clinical Guardrails / Mimics / Pitfalls
Do not base the choice solely on cost if the patient is uninsured/underinsured; consider affordability and assistance programs. Avoid assuming analog superiority in all contexts—many trials were noninferiority designs and pediatric data are limited. Do not replace basal insulin with rapid-acting analog; ensure proper pre-meal timing. Monitor for hypoglycemia regardless of insulin type.
## Concrete Clinical Example
A 45-year-old adult with type 1 diabetes on basal-bolus therapy reports a history of severe hypoglycemia requiring assistance, has IAH, and has stage 3 chronic kidney disease. The clinician selects insulin aspart for prandial bolus dosing.
**Source:** Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596
